Central Alerting System
View Alert

Originator: CMO Messaging

From: Professor Chris Whitty

Issue date: 18-Aug-2020 10:33:09

This alert has been issued to:
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Primary Care Networks
  • GP Practices 1

Action category: Important information for immediate action

Title: COVID-19 Research and treatment trials

Broadcast content: Thank you for your efforts in facilitating research on COVID-19 in the NHS, which has informed clinical practice worldwide. The attached outlines how important it is that COVID-19 patients are always invited to join the urgent public health (UPH) studies. It explains that RECOVERY will continue to be supported as the national clinical trial platform for COVID-19 phase III therapeutics trials and will also be extended to include phase II trials. And that with upcoming vaccine studies and a need to restart non-COVID-19 research that was paused it is vital that research delivery staff and clinical academics return from frontline and other duties and resume their research. 

Alert reference: CEM/CMO/2020/032


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency